Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

• Robert Brown,
• Christina Yap,
• Johann De Bono,
• Malaka Ameratunga,
• Anna Minchom,
• Wei Yuan,
• Mateus Crespo,
• Bora Gurel,
• Ines Figueiredo,
• Susana Miranda,
• Ruth Riisnaes,
• Ana Ferreira,
• Claudia Bertan,
• Rita Pereira,
• Chloe Baker,
• Nina Tunariu,
• Suzanne Carreira,
• Udai Banerji,
• Juanita Lopez,
• Alison Turner,
• Wentin Chen,
• Abhijit Pal,
• Dionysis Papadatos-Pastos,
• Toby Prout,
• Maxime Chénard-Poirier,
• Andra Curcean,
• Nahal Masrour,
• Ricardo Morilla,
• Ben Jenkins,
• Anna Zachariou,
• Mona Parmar

Affiliations

Robert Brown

Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, New York, USA

Christina Yap

Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK

Johann De Bono

Institute of Cancer Research, London, UK

Malaka Ameratunga

Aff555 grid.410678.cAustin Health and Olivia Newton-John Cancer Research Institute Melbourne Victoria Australia

Anna Minchom

Institute of Cancer Research, London, UK

Wei Yuan

Emergency Medicine Clinical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

Mateus Crespo

Drug Development Unit, Royal Marsden Hospital/ Institute of Cancer Research, Sutton, UK

Bora Gurel

Drug Development Unit, Royal Marsden Hospital/ Institute of Cancer Research, Sutton, UK

Ines Figueiredo

Drug Development Unit, Royal Marsden Hospital/ Institute of Cancer Research, Sutton, UK

Susana Miranda

Drug Development Unit, Royal Marsden Hospital/ Institute of Cancer Research, Sutton, UK

Ruth Riisnaes

Drug Development Unit, Royal Marsden Hospital/ Institute of Cancer Research, Sutton, UK

Ana Ferreira

Drug Development Unit, Royal Marsden Hospital/ Institute of Cancer Research, Sutton, UK

Claudia Bertan

Drug Development Unit, Royal Marsden Hospital/ Institute of Cancer Research, Sutton, UK

Rita Pereira

Drug Development Unit, Royal Marsden Hospital/ Institute of Cancer Research, Sutton, UK

Chloe Baker

Drug Development Unit, Royal Marsden Hospital/ Institute of Cancer Research, Sutton, UK

Nina Tunariu

Drug Development Unit, Royal Marsden Hospital/ Institute of Cancer Research, Sutton, UK

Suzanne Carreira

Drug Development Unit, Royal Marsden Hospital/ Institute of Cancer Research, Sutton, UK

Udai Banerji

Institute of Cancer Research, London, UK

Juanita Lopez

Institute of Cancer Research, London, UK

Alison Turner

2The Strategy Unit, NHS Midlands and Lancashire Commissioning Support Unit, West Bromwich, UK

Wentin Chen

College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

Abhijit Pal

Institute of Cancer Research, London, UK

Dionysis Papadatos-Pastos

Clinical Research Facility, University College London Hospitals, London, UK

Toby Prout

Drug Development Unit - Investigator Initiated Trials Team, Institute of Cancer Research, Sutton, UK

Maxime Chénard-Poirier

Drug Development Unit, Royal Marsden Hospital/Institute of Cancer Research, Sutton, UK

Andra Curcean

Drug Development Unit, Royal Marsden Hospital/Institute of Cancer Research, Sutton, UK

Nahal Masrour

Department of Surgery and Cancer, Imperial College London, London, UK

Ricardo Morilla

Drug Development Unit, Royal Marsden Hospital/Institute of Cancer Research, Sutton, UK

Ben Jenkins

Clinical Trials and Statistics Unit, Institute of Cancer Research, Sutton, UK

Anna Zachariou

Drug Development Unit - Investigator Initiated Trials Team, Institute of Cancer Research, Sutton, UK

Mona Parmar

Drug Development Unit - Investigator Initiated Trials Team, Institute of Cancer Research, Sutton, UK